Aquestive Therapeutics, Inc. named Carl N. Kraus, M.D. as chief medical officer, effective June 26, 2023. Dr. Kraus joins the Aquestive team from Aceragen, where he served as Chief Medical Officer from October 2021 to April 2023. Prior to that, Dr. Kraus founded and served as the Chief Executive Officer of Arrevus from January 2017 until the sale of Arrevus to Aceragen in October 2021.

He previously served as Chief Medical Officer of Ology Bioservices (formerly Nanotherapeutics), which was acquired by National Resilience. Prior to joining the pharmaceutical industry, Dr. Kraus was a Medical Officer for the Center of Drug Evaluation and Research (CDER). Earlier in his career, he held inpatient and outpatient clinical appointments.

Dr. Kraus earned his medical doctor degree from Washington University School of Medicine in St. Louis, MO, with post-graduate training in Internal Medicine (University of Chicago) and Infectious Diseases (National Institutes of Health).